Pfizer triumphs at environmental awards
The best in UK environmental excellence was celebrated on 1 July at the 2009 Business Commitment to the Environment (BCE) Environmental Leadership Awards in London...best in UK environmental excellence was celebrated on 1 July at the 2009 Business Commitment to the Environment (BCE) Environmental Leadership Awards in London...
read more

_____________________________

BASi opens new facility in Europe to better serve pharmaceutical and biotech companies
BASi, a leading provider of contract laboratory services and manufacturer of scientific instruments in the US, has opened a new European laboratory and office in Warwickshire, UK...
read more

_____________________________

IChemE President awarded CBE
IChemE President, Ian Shott has been awarded a CBE (Commander of the British Empire) in recognition of his services to the chemical engineering industry...
read more

_____________________________

ICON Announces Collaboration to Develop New Translational Medicine Unit at Purpose-built Hospital Facility in Manchester
Dublin, Ireland, June 16th, 2009 ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a collaborative agreement with the Central Manchester University Hospitals Foundation (CMFT) to develop a purpose built translational medicine facility...
read more

_____________________________

Biopartners Appoints Dr Conrad Savoy as CEO
Biopartners GmbH has announced the appointment of Dr Conrad Savoy as its new CEO and President of the Board from the 1st of May 2009...
read more

_____________________________

Cancer Congress Update set to launch in UK
The programme for the UK's first Cancer Congress Update (CCU) has been announced...
read more

_____________________________

Heptares moves to Welwyn BioPark and plans further expansion
Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announces that it is relocating to the BioPark in Welwyn Garden City, between London and Cambridge, from its laboratories in Mill Hill, North London, where it has been based since founding in 2007...
read more

_____________________________

>>Read more news stories                                                                   

Welcome back to the European Pharmaceutical Review site!

As we all know it has been a some what difficult few weeks for many politicians in the UK and now a large percentage of voters have retaliated to the outlandish expenses claims (Duck Island anybody?) by not voting for the ‘big three' parties.

Europe is now looking at a different parliament where right-wing parties are more prominent and Labour is not such a strong force. Whether this is a step forward or back for the EU is a huge talking point but how will this new style of European Parliament affect European science?

This week I came across a Science Blog on the Guardian website which highlighted just how little time the ‘big three' parties dedicate to scientific issues; commitment to research gets a small mention and their positions on areas such as stem cell research and genetic modification are unclear. Then there are other key parties, the Green Party for example, who are proposing an EU-wide ban on embryonic stem cell research. If our parties aren't sure where they stand on important scientific issues then where should the science community turn?

I'd love to hear your opinions on the current political status of the UK and the EU and how you think it will affect you as scientists in the future.

Interested in contributing editorial?

If you have an interesting project or any opinions that you would like to share with our readers, please contact me, I'd love to hear from you. 

 

Email me

Biomarkers in CNS drug discovery and development - focus on molecular blood markers
Irina Antonijevic, Director of Translational Research, Lundbeck Research USA

In established economies, mental disorders account for a larger burden of disease than all cancers combined...

Read article in full
_________________________________

»11th International Congress on Amino Acids, Peptides & Proteins
Date: 3 - 7 August 2009
Location: Vienna, Austria
View Website

________

»Pharma CI
Date: 15 - 16 September 2009
Location: New Jersey
View Website  

________

»World Drug Safety Congress 
Date: 15 - 18 September 2009
Location: London, UK
View Website

________

»The World Stem Cell Summit 2009
Date: 21 - 23 September 2009
Location: Baltimore, USA
View Website 

________
     
»European Biomarkers Summit
Date: 5 - 6 November 2009
Location: Barcelona, Spain
View Website

________

»Proteomics Europe
Date: 5-6 November 2009
Location: Barcelona, Spain
View Website

________

________

»Stem Cells: A Pathway Through the Maze
Date: 10 - 11 December 2009
Location: Oxford, UK
View Website

Quantitative Proteomics for Systems Biology
Dr Claire Eyers, Deputy Director, Michael Barber Centre for Mass Spectrometry, University of Manchester

The pharmaceutical industry continues to experience a high attrition rate during the latter stages of small molecule therapeutic development, most disappointingly during the late, and highly expensive stages of Phase II and Phase III trial¹.

Read article in full
_________________________________

Cellular reprogramming and its implications for therapeutic applications
Dr Jens Schwamborn, Group Leader Münster University and Lai Wen, Visiting Scholar, Münster University

Nearly fifty years ago, it was hypothesised that terminally differentiated cells such as fibroblasts could be forced to take on a pluripotent state, similar to the embryonic stem cells (ES cells)...

Read article in full
_______________________________

High Content Analysis Roundtable
Anthony Davies, Director of High Content Research Facility, Department of Clinical Medicine, Trinity College Dublin, Sarah Payne, Product Manager, TTP LabTech Limited, Khuong Truong, European Product Manager, BD Biosciences, Jeremy Simpson, Professor of Cell Biology, University College Dublin (UCD), Oscar 'Joe' Trask, Head of Cellular Imaging Technologies, Duke University, Peter Simpson, Associate Director of Cancer Bioscience, AstraZeneca

1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques?...

Read article in full
_______________________________ 

Applying PAT in Chemical Process Development
Mario Hellings, Scientist, Tom Van den Kerkhof, Senior Scientist and Koen De Smet, Senior Technology Engineer, Johnson & Johnson

As the time-to-market of pharmaceutical products has elongated, while its prices are under big pressure, cost saving is currently essential in the pharmaceutical industry...

Read article in full

_____________________________